Aldoxorubicin
- Generic Name
- Aldoxorubicin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42N4O13
- CAS Number
- 1361644-26-9
- Unique Ingredient Identifier
- C28MV4IM0B
- Background
Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03574649
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
- Conditions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- CytRx
- Registration Number
- NCT02570412
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02235688
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02200757
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
🇺🇸Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸Oncology Hermatology Care, Inc., Cincinnati, Ohio, United States
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 433
- Registration Number
- NCT02049905
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇺🇸The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸Fletcher Allen Health Care, Burlington, Vermont, United States
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01706835
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01673438
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.